Our biotech team launched this gene therapy startup two years ago and we've developed completely different risk tolerances around patient safety data. Half of us want to push for accelerated approval based on our Phase II results and half think we need another full trial, and every safety meeting turns into the same philosophical argument about acceptable risk that we never actually resolve.
More people experience this than they realize.
Your team can't agree on how much risk is acceptable when patients' lives are at stake.
“Where Are You with Science — Biotech & Pharmaceutical R&D?”
If this sounds familiar, the Library can help you find the bigger picture.